)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Cryoport
Cryoport (CYRX) investor relations material
Cryoport Q3 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2026 earnings summary5 Nov, 2026
Executive summary
Q3 revenue rose 13.5% YoY to $50.2M, while adjusted EBITDA from continuing operations was $1.1M versus a $0.6M loss a year earlier.
Supported 23 commercial therapies and a record 788 clinical trials, including 99 Phase III trials; FY2026 revenue guidance increased to $197M–$199M.
Financial highlights
Q3 revenue was $50.2M versus $44.2M; 9M revenue increased 12.4% YoY to $147.0M.
Q3 loss from continuing operations was $10.9M versus $6.7M; net loss attributable to common stockholders was $12.9M, or $0.25 per share.
9M loss from continuing operations was $28.5M versus $25.4M; 9M net loss was $29.7M versus net income of $89.9M in 2025, which included the CRYOPDP divestiture gain.
Q3 gross profit increased 11.8% YoY to $23.8M.
Outlook and guidance
FY2026 revenue guidance rose to $197M–$199M from $192M–$196M, representing 12% organic growth at the midpoint.
Q4 guidance assumes continuation of year-to-date growth among current clients and excludes revenue from potential new therapy approvals, which may take time to ramp.
Five additional BLA/MAA filings, two potential therapy approvals and one supplemental geographic expansion approval were expected in the remainder of 2026; four anticipated filings shifted to 2027.
Management expects further EBITDA margin expansion in 2027 and beyond as BioServices capabilities come online and utilization increases.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Cryoport
- Q2 2026 revenue up 8% to $49M, adjusted EBITDA positive, and strong liquidity maintained.CYRX
Q2 2026 - Leading CGT supply chain provider projects strong growth, margin expansion, and digital integration.CYRXInvestor presentation
- Global C> supply chain leader with 17 commercial therapies, $56.7M Q3 revenue, and rapid sector growth.CYRXInvestor presentation
- All management proposals passed, including director elections and equity plan amendment.CYRXAGM 2026
- 16% revenue growth and 70% CGT trial share highlight strong momentum and global expansion.CYRXCorporate presentation
- Q1 2026 revenue up 16–16.5%, guidance raised, and profitability expected in H2 2026.CYRXQ1 2026
- FY2025 revenue rose 12% to $176.2M, with margin expansion and strong CGT market growth.CYRXQ4 2025
- Q3 2024 revenue grew 1% as services outpaced products, margins improved, and guidance was reaffirmed.CYRXQ3 2024
- Q2 2024 revenue hit $57.6M; strong cell therapy growth, $63.8M impairment, $22M cost savings targeted.CYRXQ2 2024
Next Cryoport earnings date
Q4 20263 Mar, 2027
Cryoport
Next Cryoport earnings date
Q4 20263 Mar, 2027
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Cryoport Inc is a global provider of temperature-controlled supply chain solutions, primarily serving the life sciences industry. The company specializes in supporting the logistics of temperature-sensitive materials, including those vital for cell and gene therapies, biopharmaceuticals, in vitro fertilization (IVF), surrogacy, and animal health sectors. Its services are crucial in maintaining the integrity of biological samples and products through the use of advanced cryogenic logistics solutions. Cryoport manages these shipments through its Cryoportal, a cloud-based logistics management platform that ensures the secure and efficient transport of life sciences commodities worldwide. The platform offers comprehensive management of shipment processes, including order entry, document preparation, customs documentation, courier management, real-time tracking, and regulatory compliance. The company is headquartered in Nashville, TN, and its shares are listed on the Nasdaq.